103 related articles for article (PubMed ID: 28338310)
21. The prostate-specific antigen test.
Roobol MJ
Expert Opin Med Diagn; 2013 Sep; 7(5):423-6. PubMed ID: 23875974
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
24. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
25. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
[TBL] [Abstract][Full Text] [Related]
26. Predictors of androgen independence in metastatic prostate cancer.
Sim HG; Lau WK; Cheng CW
BJU Int; 2004 Jun; 93(9):1221-4. PubMed ID: 15180610
[TBL] [Abstract][Full Text] [Related]
27. Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
van Leeuwen PJ; van den Bergh RC; Wolters T; Zhu X; Bul M; Schröder FH; Bangma CH; Roobol MJ
Can J Urol; 2011 Dec; 18(6):6018-24. PubMed ID: 22166329
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.
Scosyrev E; Wu G; Mohile S; Messing EM
Cancer; 2012 Dec; 118(23):5768-76. PubMed ID: 22847578
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
Bunting PS; Goel V; Williams JI; Iscoe NA
CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
[TBL] [Abstract][Full Text] [Related]
30. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
[TBL] [Abstract][Full Text] [Related]
31. [The role of PSA in diagnosis of prostate cancer and its recurrence].
Vergho DC; Heine K; Wolff JM
Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
[TBL] [Abstract][Full Text] [Related]
32. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
33. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
Martin NE; Chen MH; Catalona WJ; Loeb S; Roehl KA; D'Amico AV
Cancer; 2008 Aug; 113(4):717-22. PubMed ID: 18615505
[TBL] [Abstract][Full Text] [Related]
34. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
[TBL] [Abstract][Full Text] [Related]
35. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer in Saskatchewan Canada, before and during the PSA era.
Skarsgard D; Tonita J
Cancer Causes Control; 2000 Jan; 11(1):79-88. PubMed ID: 10680732
[TBL] [Abstract][Full Text] [Related]
37. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
40. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]